Contributions
Abstract: P317
Type: Poster
Abstract Category: Clinical aspects of MS - Epidemiology
Background: Data on whether the accumulation of disability and relapse may be influenced by serum lipid levels and body mass index (BMI) in patients with a first clinical diagnosis of demyelination is limited. We aimed to investigate whether there were any associations between lipid-related variables at cohort entry and conversion to clinically definite MS (CDMS), time to subsequent relapse and progression in disability.
Methods: A cohort of 279 patients with a first clinical diagnosis of demyelination from the Ausimmune Study was prospectively followed up to 5-year review. Height and weight were measured and serum samples taken at baseline to measure lipid profile and apolipoprotein levels. Associations with conversion to CDMS and hazard of relapse were assessed using survival analysis and associations with annual change in disability were evaluated using linear regression.
Results: Higher body mass index (BMI) (Adjusted hazard ratio (AHR) 1.04 (95% CI 1.01, 1.08) p=0.014) and triglyceride levels (AHR 1.20 (95% CI 1.03, 1.40) p=0.021) at cohort entry were associated with increased risk of subsequent relapse while lipid-related measures were not significantly associated with conversion to CDMS. In addition, higher BMI (β 0.01 (95% CI 0.001, 0.13) p=0.010) and the ratio of total cholesterol over high density lipoprotein (TC/HDL ratio) (β 0.05 (95% CI 0.001, 0.10) p=0.044) at cohort entry were associated with a higher subsequent annual change in disability.
Conclusions: In this prospective study, we have demonstrated that higher BMI and triglycerides at first clinical diagnosis of CNS demyelination were associated with increased hazard of relapse, and a higher BMI and TC/HDL ratio were associated with a higher rate in disability progression. Improving lipid profile and losing weight into the healthy range may improve the disease course of MS.
Disclosure: Authors have no relevant disclosures.
Abstract: P317
Type: Poster
Abstract Category: Clinical aspects of MS - Epidemiology
Background: Data on whether the accumulation of disability and relapse may be influenced by serum lipid levels and body mass index (BMI) in patients with a first clinical diagnosis of demyelination is limited. We aimed to investigate whether there were any associations between lipid-related variables at cohort entry and conversion to clinically definite MS (CDMS), time to subsequent relapse and progression in disability.
Methods: A cohort of 279 patients with a first clinical diagnosis of demyelination from the Ausimmune Study was prospectively followed up to 5-year review. Height and weight were measured and serum samples taken at baseline to measure lipid profile and apolipoprotein levels. Associations with conversion to CDMS and hazard of relapse were assessed using survival analysis and associations with annual change in disability were evaluated using linear regression.
Results: Higher body mass index (BMI) (Adjusted hazard ratio (AHR) 1.04 (95% CI 1.01, 1.08) p=0.014) and triglyceride levels (AHR 1.20 (95% CI 1.03, 1.40) p=0.021) at cohort entry were associated with increased risk of subsequent relapse while lipid-related measures were not significantly associated with conversion to CDMS. In addition, higher BMI (β 0.01 (95% CI 0.001, 0.13) p=0.010) and the ratio of total cholesterol over high density lipoprotein (TC/HDL ratio) (β 0.05 (95% CI 0.001, 0.10) p=0.044) at cohort entry were associated with a higher subsequent annual change in disability.
Conclusions: In this prospective study, we have demonstrated that higher BMI and triglycerides at first clinical diagnosis of CNS demyelination were associated with increased hazard of relapse, and a higher BMI and TC/HDL ratio were associated with a higher rate in disability progression. Improving lipid profile and losing weight into the healthy range may improve the disease course of MS.
Disclosure: Authors have no relevant disclosures.